{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:45:45Z","timestamp":1793065545050,"version":"4.5.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01261","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T19:41:14Z","timestamp":1593200474000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":85,"title":["Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation"],"prefix":"10.3389","volume":"11","author":[{"given":"Ronit","family":"Mazor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.clinthera.2015.06.004","article-title":"Enzyme replacement therapies and immunogenicity in lysosomal storage diseases: is there a pattern?","volume":"37","author":"Harmatz","year":"2015","journal-title":"Clin Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/imr.12390","article-title":"Immunogenicity of therapeutic recombinant immunotoxins","volume":"270","author":"Mazor","year":"2016","journal-title":"Immunol Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2174\/1566523023347616","article-title":"Immunogenic issues concerning recombinant adeno-associated virus vectors for gene therapy","volume":"2","author":"Sun","year":"2002","journal-title":"Curr Gene Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1517\/14712598.6.8.787","article-title":"Development of antibodies for cancer therapy","volume":"6","author":"Wilkins","year":"2006","journal-title":"Expert Opin Biol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies","volume":"18","author":"Kreitman","year":"2000","journal-title":"J Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1182\/blood-2014-01-492256","article-title":"Immunotoxins for leukemia","volume":"123","author":"Wayne","year":"2014","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1182\/blood.V85.12.3457.bloodjournal85123457","article-title":"Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study","volume":"85","author":"Sausville","year":"1995","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1023\/B:BREA.0000004371.48757.19","article-title":"Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2\/HER2","volume":"82","author":"Azemar","year":"2003","journal-title":"Breast Cancer Res Treat."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.3389\/fmicb.2019.02340","article-title":"Targeted diphtheria toxin-based therapy: a review article","volume":"10","author":"Shafiee","year":"2019","journal-title":"Front Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.bbmt.2018.10.020","article-title":"Phase I\/II trial of a combination of anti-CD3\/CD7 immunotoxins for steroid-refractory acute graft-versus-host disease","volume":"25","author":"Groth","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1000803","DOI":"10.1371\/journal.ppat.1000803","article-title":"Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs","volume":"6","author":"Berger","year":"2010","journal-title":"PLoS Pathog."},{"key":"B14","doi-asserted-by":"publisher","first-page":"14321","DOI":"10.1038\/ncomms14321","article-title":"Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein","volume":"8","author":"Krishna","year":"2017","journal-title":"Nat Commun."},{"key":"B15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41551-019-0360-0","article-title":"Depletion of PD-1-positive cells ameliorates autoimmune disease","volume":"3","author":"Zhao","year":"2019","journal-title":"Nat Biomed Eng."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3390\/toxins5081486","article-title":"Immunotoxins: the role of the toxin","volume":"5","author":"Antignani","year":"2013","journal-title":"Toxins (Basel)."},{"key":"B17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1586\/14737140.5.1.33","article-title":"Denileukin diftitox: a concise clinical review","volume":"5","author":"Eklund","year":"2005","journal-title":"Expert Rev Anticancer Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1177\/1078155219838041","article-title":"Moxetumomab pasudotox: a first-in-class treatment for hairy cell leukemia","volume":"25","author":"Fancher","year":"2019","journal-title":"J Oncol Pharm Pract."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1158\/1078-0432.CCR-12-3891","article-title":"Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy","volume":"19","author":"Chandramohan","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nm0396-350","article-title":"Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin","volume":"2","author":"Pai","year":"1996","journal-title":"Nat Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/bjc.2015.380","article-title":"Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin","volume":"113","author":"Andersson","year":"2015","journal-title":"Br J Cancer."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1634\/theoncologist.2019-0370","article-title":"Contextualizing the use of moxetumomab pasudotox in the treatment of relapsed or refractory hairy cell leukemia","volume":"25","author":"Kreitman","year":"2020","journal-title":"Oncologist."},{"key":"B23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1078-0432.CCR-15-1412","article-title":"Complete remissions of adult T-cell leukemia with anti-CD25 recombinant immunotoxin LMB-2 and chemotherapy to block immunogenicity","volume":"22","author":"Kreitman","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1158\/1538-7445.PANCA19-PR07","article-title":"Phase I\/II study of the mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma","volume":"26","author":"Alewine","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-018-1000-9","article-title":"Moxetumomab pasudotox: first global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1182\/bloodadvances.2019000507","article-title":"Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval","volume":"3","author":"Lin","year":"2019","journal-title":"Blood Adv."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1200\/JCO.1991.9.12.2095","article-title":"Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer","volume":"9","author":"Pai","year":"1991","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of mesothelin in epithelial ovarian cancer","volume":"13","author":"Hassan","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Tang","year":"2013","journal-title":"Anticancer Agents Med Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1158\/1535-7163.MCT-14-0132","article-title":"Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers","volume":"13","author":"Alewine","year":"2014","journal-title":"Mol Cancer Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1158\/1535-7163.MCT-14-0089-T","article-title":"In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer","volume":"13","author":"Hollevoet","year":"2014","journal-title":"Mol Cancer Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3389\/fmicb.2015.00963","article-title":"Pseudomonas exotoxin A: optimized by evolution for effective killing","volume":"6","author":"Michalska","year":"2015","journal-title":"Front Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ijmm.2008.08.003","article-title":"Pseudomonas exotoxin A: from virulence factor to anti-cancer agent","volume":"299","author":"Wolf","year":"2009","journal-title":"Int J Med Microbiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"112688","DOI":"10.1016\/j.jim.2019.112688","article-title":"A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains","volume":"477","author":"Vainshtein","year":"2019","journal-title":"J Immunol Methods."},{"key":"B36","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jim.2016.05.007","article-title":"An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox","volume":"435","author":"Schneider","year":"2016","journal-title":"J Immunol Methods."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.ajpath.2018.04.016","article-title":"Strategies to reduce the immunogenicity of recombinant immunotoxins","volume":"188","author":"Mazor","year":"2018","journal-title":"Am J Pathol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","article-title":"Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia","volume":"30","author":"Kreitman","year":"2012","journal-title":"J Clin Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.1200\/JCO.2005.11.437","article-title":"Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies","volume":"23","author":"Kreitman","year":"2005","journal-title":"J Clin Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia."},{"key":"B41","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.4049\/jimmunol.179.7.4919","article-title":"Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo","volume":"179","author":"Powell","year":"2007","journal-title":"J Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.anai.2016.05.013","article-title":"Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist","volume":"117","author":"Khan","year":"2016","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/asheducation.V2012.1.660.3798659","article-title":"Immunoconjugates and new molecular targets in hairy cell leukemia","volume":"2012","author":"Kreitman","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B44","doi-asserted-by":"publisher","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci Transl Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1078-0432.CCR-1160-3","article-title":"Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin Cancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.4049\/jimmunol.1402324","article-title":"Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice","volume":"194","author":"Manning","year":"2015","journal-title":"J Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4049\/jimmunol.1400063","article-title":"Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts","volume":"193","author":"Onda","year":"2014","journal-title":"J Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology (Oxford)."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/apt.13994","article-title":"Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease","volume":"45","author":"Strik","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.4049\/jimmunol.1701430","article-title":"Low-dose methotrexate prevents primary and secondary humoral immune responses and induces immune tolerance to a recombinant immunotoxin","volume":"200","author":"King","year":"2018","journal-title":"J Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"E733","DOI":"10.1073\/pnas.1717063115","article-title":"Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity","volume":"115","author":"Mazor","year":"2018","journal-title":"Proc Natl Acad Sci USA."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods."},{"key":"B55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs."},{"key":"B56","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.addr.2009.07.014","article-title":"Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics","volume":"61","author":"Nagata","year":"2009","journal-title":"Adv Drug Deliv Rev."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.molonc.2016.07.003","article-title":"Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy","volume":"10","author":"Bauss","year":"2016","journal-title":"Mol Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1126\/science.2410982","article-title":"Intrinsic and extrinsic factors in protein antigenic structure","volume":"229","author":"Berzofsky","year":"1985","journal-title":"Science."},{"key":"B59","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1128\/IAI.62.11.5055-5065.1994","article-title":"Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin","volume":"62","author":"Roscoe","year":"1994","journal-title":"Infect Immun."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/eji.1830270624","article-title":"Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins","volume":"27","author":"Roscoe","year":"1997","journal-title":"Eur J Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"8822","DOI":"10.4049\/jimmunol.177.12.8822","article-title":"Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients","volume":"177","author":"Onda","year":"2006","journal-title":"J Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"11311","DOI":"10.1073\/pnas.0804851105","article-title":"An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes","volume":"105","author":"Onda","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B63","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1111\/j.1742-4658.2011.08182.x","article-title":"A guide to taming a toxin\u2013recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer","volume":"278","author":"Weldon","year":"2011","journal-title":"FEBS J."},{"key":"B64","doi-asserted-by":"publisher","first-page":"11782","DOI":"10.1073\/pnas.1209292109","article-title":"Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes","volume":"109","author":"Liu","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B65","doi-asserted-by":"publisher","first-page":"8571","DOI":"10.1073\/pnas.1405153111","article-title":"Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes","volume":"111","author":"Mazor","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B66","doi-asserted-by":"publisher","first-page":"29916","DOI":"10.18632\/oncotarget.9171","article-title":"Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity","volume":"7","author":"Mazor","year":"2016","journal-title":"Oncotarget."},{"key":"B67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cellimm.2017.01.003","article-title":"Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38","volume":"313","author":"Mazor","year":"2017","journal-title":"Cell Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1158\/1535-7163.MCT-17-1041","article-title":"Improving the in vivo efficacy of an anti-Tac (CD25) immunotoxin by Pseudomonas exotoxin A domain II engineering","volume":"17","author":"Kaplan","year":"2018","journal-title":"Mol Cancer Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/abt\/tby004","article-title":"Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma","volume":"1","author":"Shancer","year":"2018","journal-title":"Antib Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/hep.30949","article-title":"Engineered anti-GPC3 immunotoxin, HN3-ABD-T20, produces regression in mouse liver cancer xenografts through prolonged serum retention","volume":"71","author":"Fleming","year":"2019","journal-title":"Hepatology."},{"key":"B71","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.3390\/toxins7104067","article-title":"Mutagenic deimmunization of diphtheria toxin for use in biologic drug development","volume":"7","author":"Schmohl","year":"2015","journal-title":"Toxins (Basel)."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1182\/blood-2008-08-173195","article-title":"A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity","volume":"113","author":"Weldon","year":"2009","journal-title":"Blood."},{"key":"B73","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/CJI.0b013e3181cd1164","article-title":"A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice","volume":"33","author":"Hansen","year":"2010","journal-title":"J Immunother."},{"key":"B74","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/274092a0","article-title":"Evolutionary substitutions and the antigenic structure of globular proteins","volume":"274","author":"White","year":"1978","journal-title":"Nature."},{"key":"B75","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.4049\/jimmunol.172.11.6658","article-title":"Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope","volume":"172","author":"Yeung","year":"2004","journal-title":"J Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/cmi.2015.91","article-title":"Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo","volume":"14","author":"Mazor","year":"2017","journal-title":"Cell Mol Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1074\/jbc.RA118.006704","article-title":"Deimmunizing substitutions in Pseudomonas exotoxin domain III perturb antigen processing without eliminating T-cell epitopes","volume":"294","author":"Moss","year":"2019","journal-title":"J Biol Chem."},{"key":"B78","doi-asserted-by":"publisher","first-page":"943","DOI":"10.4049\/jimmunol.1000405","article-title":"Molecular determinants of T cell epitope recognition to the common Timothy grass allergen","volume":"185","author":"Oseroff","year":"2010","journal-title":"J Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"E3597","DOI":"10.1073\/pnas.1218138109","article-title":"Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A","volume":"109","author":"Mazor","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B80","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jim.2005.07.014","article-title":"Monitoring of cellular responses after vaccination against tetanus toxoid: comparison of the measurement of IFN-gamma production by ELISA, ELISPOT, flow cytometry and real-time PCR","volume":"305","author":"Tassignon","year":"2005","journal-title":"J Immunol Methods."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/bioinformatics\/17.12.1236","article-title":"ProPred: prediction of HLA-DR binding sites","volume":"17","author":"Singh","year":"2001","journal-title":"Bioinformatics."},{"key":"B82","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/1471-2105-11-568","article-title":"Peptide binding predictions for HLA DR, DP and DQ molecules","volume":"11","author":"Wang","year":"2010","journal-title":"BMC Bioinformatics."},{"key":"B83","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jim.2015.06.003","article-title":"Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A","volume":"425","author":"Mazor","year":"2015","journal-title":"J Immunol Methods."},{"key":"B84","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1208\/s12248-016-9986-y","article-title":"Role of HLA-DP in the presentation of epitopes from the truncated bacterial PE38 immunotoxin","volume":"19","author":"Mazor","year":"2017","journal-title":"AAPS J."},{"key":"B85","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1073\/pnas.1321126111","article-title":"Removing T-cell epitopes with computational protein design","volume":"111","author":"King","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1158\/1535-7163.MCT-15-0532","article-title":"Recombinant immunotoxin with T-cell epitope mutations that greatly reduce immunogenicity for treatment of mesothelin-expressing tumors","volume":"14","author":"Mazor","year":"2015","journal-title":"Mol Cancer Ther."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/jmbi.1998.1843","article-title":"Anatomy of hot spots in protein interfaces","volume":"280","author":"Bogan","year":"1998","journal-title":"J Mol Biol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1745-7580-6-6","article-title":"Identification of conformational B-cell epitopes in an antigen from its primary sequence","volume":"6","author":"Ansari","year":"2010","journal-title":"Immunome Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.1073\/pnas.1102746108","article-title":"Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes","volume":"108","author":"Onda","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B90","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.4049\/jimmunol.143.8.2663","article-title":"I-Ad restricted T cell recognition of influenza hemagglutinin. Synthetic peptides identify multiple epitopes corresponding to antibody-binding regions of the HA1 subunit","volume":"143","author":"Barnett","year":"1989","journal-title":"J Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.4049\/jimmunol.168.5.2530","article-title":"Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus","volume":"168","author":"Kaliyaperumal","year":"2002","journal-title":"J Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e0115582","DOI":"10.1371\/journal.pone.0115582","article-title":"Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B\/E","volume":"10","author":"Ratto-Kim","year":"2015","journal-title":"PLoS ONE."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e65748","DOI":"10.1371\/journal.pone.0065748","article-title":"Shaping T cell\u2013B cell collaboration in the response to human immunodeficiency virus type 1 envelope glycoprotein gp120 by peptide priming","volume":"8","author":"Steede","year":"2013","journal-title":"PLoS ONE."},{"key":"B94","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a Bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin Cancer Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clin Cancer Res."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01261\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:25:10Z","timestamp":1696292710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01261\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":95,"alternative-id":["10.3389\/fimmu.2020.01261"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01261","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"article-number":"1261"}}